Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $40 | $44 | $31 | $32 |
| G&A Expenses | $6 | $4 | $4 | $4 |
| SG&A Expenses | $6 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $46 | $48 | $35 | $37 |
| Operating Income | -$46 | -$48 | -$35 | -$37 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $4 | $4 | $3 |
| Pre-Tax Income | -$42 | -$44 | -$30 | -$34 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$42 | -$44 | -$30 | -$34 |
| % Margin | – | – | – | – |
| EPS | -0.49 | -0.51 | -0.36 | -0.57 |
| % Growth | 3.9% | -41.7% | 36.8% | – |
| EPS Diluted | -0.49 | -0.51 | -0.36 | -0.57 |
| Weighted Avg Shares Out | 86 | 85 | 85 | 59 |
| Weighted Avg Shares Out Dil | 86 | 85 | 85 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $4 | $5 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$42 | -$48 | -$35 | -$37 |
| % Margin | – | – | – | – |